Xencor Stock Price, News & Analysis

Xencor (NASDAQ:XNCR) announced management will participate in two investor conferences in late 2025: the TD Cowen Immunology and Inflammation Virtual Summit on Wednesday, November 12, 2025 at 3:00 p.m. ET / 12:00 p.m. PT, and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET / 11:00 a.m. PT.

Both presentations will be available via live webcast under the company’s Investors & Events section at www.xencor.com. Replays will be posted on the Xencor website for at least 30 days after the events.

Xencor (NASDAQ:XNCR) reported third quarter 2025 results and clinical updates on November 5, 2025. Q3 revenue was $21.0M vs $17.8M year-ago. Cash, cash equivalents and marketable debt securities were $633.9M at September 30, 2025 and the company expects to end 2025 with $570M–$590M, providing runway into 2028. Net loss was $6.0M, or $(0.08) per share, versus $(0.72) in Q3 2024. Other income increased to $41.5M driven by unrealized gains.

Clinical: XmAb819 and XmAb541 showed early anti-tumor activity with planned recommended Phase 3 dose selection in 2026 and pivotal study starts in 2027; XmAb942 and plamotamab advanced into Phase 2b and Phase 1b studies, respectively.

Xencor (NASDAQ:XNCR) reported initial Phase 1 data for XmAb819, an ENPP3 x CD3 T-cell engager in development for advanced clear cell renal cell carcinoma (ccRCC), with results current as of Sept 19, 2025. Across 69 patients in 10 IV and 5 SC cohorts, XmAb819 showed a 25% overall response rate (5/20) and a 70% disease control rate (14/20) within the preclinically predicted target dose range. Safety was generally tolerable; common TEAEs included CRS, rash and GI events, mostly Grade 1–2. Notable safety signals: Grade 3 rash 16%, Grade 3 liver enzyme elevations 7%, one Grade 4 DLT (elevated liver enzymes), and no ICANS or Grade 5 events. Dose-expansion is underway and a recommended Phase 3 dose is expected to be selected during 2026.

Xencor (NASDAQ:XNCR) will host a live webcast and conference call on Friday, October 24, 2025 at 1:30 p.m. ET to discuss initial results from the ongoing Phase 1 dose‑escalation study of XmAb819, an ENPP3 x CD3 T‑cell engaging bispecific antibody for advanced clear cell renal cell carcinoma (ccRCC).

The same data will be presented as a poster at the AACR‑NCI‑EORTC Conference in Boston during Poster Session B on October 24, 12:30–4:00 p.m. ET (poster title: “Preliminary Phase 1 safety and antitumor activity of XmAb819…in patients with advanced ccRCC”).

The webcast is available via the company investor website and a recording will be posted for at least 30 days.

Xencor (NASDAQ:XNCR) will present initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3 bispecific) in patients with advanced clear cell renal cell carcinoma (ccRCC) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The poster (Session: Poster Session B) is scheduled for Friday, October 24, 2025, 12:30–4:00 p.m. ET. Xencor submitted a placeholder abstract based on a prior data cut; full conference abstracts are due October 22, 2025 at 12:00 p.m. ET. An updated dataset with detailed safety analysis and efficacy from the target dose range will be presented when the conference embargo lifts. Management will host a webcast and conference call to discuss results; access details will be provided later.

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune disease treatments, has announced its participation in two major healthcare investor conferences in September 2025.

The company will present at the 2025 Wells Fargo Healthcare Conference on September 3 at 3:00 p.m. ET, followed by a presentation at the Cantor Global Healthcare Conference 2025 on September 4 at 8:00 a.m. ET. Both presentations will be available via webcast on Xencor's website, with replays accessible for 30 days after the events.

Xencor (NASDAQ:XNCR) reported Q2 2025 financial results and clinical program updates. The company recorded revenue of $43.6 million, up from $23.9 million in Q2 2024, and a net loss of $30.8 million. Cash position stands at $663.8 million, expected to fund operations into 2028.

Key clinical developments include progress in four wholly owned XmAb® programs: XmAb819 and XmAb541 for cancer treatment, with initial XmAb819 data expected in Q4 2025; the Phase 2b XENITH-UC study of XmAb942 for ulcerative colitis; and plamotamab for rheumatoid arthritis. Additionally, Xencor received a $25 million milestone payment from Incyte following FDA approval of Monjuvi for follicular lymphoma.

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, has appointed Dr. Raymond J. Deshaies to its board of directors. Dr. Deshaies brings over 25 years of biotechnology and drug development experience, most recently serving as senior vice president of global research at Amgen.

During his tenure at Amgen, Dr. Deshaies oversaw the nomination of over 50 clinical candidates and expanded capabilities in multispecific drug discovery. His notable achievements include co-founding Proteolix, which developed KYPROLIS® for multiple myeloma treatment, and founding Cleave Biosciences. He is a distinguished member of both the American Academy of Arts and Sciences and the National Academy of Sciences.

Xencor (NASDAQ:XNCR) reported its Q1 2025 financial results and business updates. The company's XmAb942 Phase 1 study showed promising results, supporting a 12-week maintenance dosing interval for ulcerative colitis treatment, with Phase 2b XENITH-UC study planned for H2 2025. Chief Development Officer Nancy Valente will transition to a senior advisory role in June 2025. Financially, Xencor reported Q1 2025 revenue of $32.7M (up from $16.0M in Q1 2024), with a net loss of $48.4M ($0.66 per share). The company maintains a strong cash position of $693.5M as of March 31, 2025, expecting to fund operations into 2028. Notable partnership developments include milestone payments from Incyte ($12.5M) and Vir Biotechnology ($2.0M).